Ultra-Low-Dose Immunotherapy Shows Clinical Activity Across Multiple Trials

Three recent clinical trials have demonstrated that substantially reduced doses of immune checkpoint inhibitors can retain clinical efficacy while dramatically improving safety and affordability, challenging conventional assumptions about optimal immunotherapy dosing.

The DELII phase III trial (Development of Low-Dose Immunotherapy in India), an open-label randomized study conducted at Tata Memorial Hospital in Mumbai between 2020 and 2024, enrolled 500 heavily pretreated patients with relapsed refractory solid tumors, including head and neck cancer, non–small cell lung cancer, esophageal cancer, urothelial carcinoma, and MSI-high tumors. Patients were randomized to receive either ultra-low-dose nivolumab 20 mg IV every two weeks (approximately one-twelfth of the conventional dose) or standard chemotherapy with docetaxel or paclitaxel. The primary endpoint was overall survival.

The DELII trial met its primary endpoint with a statistically significant improvement in overall survival: median overall survival reached 5.88 months with ultra-low-dose nivolumab versus 4.70 months with chemotherapy (hazard ratio for death 0.80). One-year overall survival was 27.3% with ultra-low-dose nivolumab versus 16.9% with chemotherapy. The benefit was observed despite using only approximately 8% of the conventional nivolumab dose. Progression-free survival did not significantly differ between arms (approximately two months in both groups), and objective response rates were similar (7.1% vs 8.1%), though duration of response was longer with ultra-low-dose nivolumab at 8.28 months versus 4.93 months with chemotherapy.

A separate landmark phase III randomized study led by Patil et al., published in the Journal of Clinical Oncology (2023), tested ultra-low-dose nivolumab specifically in recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). In this trial, 151 patients received triple metronomic chemotherapy (methotrexate, celecoxib, and erlotinib) either alone or in combination with ultra-low-dose nivolumab at 20 mg every three weeks, representing only approximately 6–10% of conventional dose intensity. The addition of low-dose nivolumab resulted in one-year overall survival of 43.4% versus 16.3%, median overall survival of 10.1 versus 6.7 months, and median progression-free survival of 6.6 versus 4.6 months. Grade ≥ 3 toxicities remained comparable between arms. Cohort analyses of stage III–IVB disease treated with low-dose nivolumab-based induction therapy reported an overall response rate of approximately 75%, conversion to resectability of approximately 32%, pathologic complete response of approximately 32%, and one-year overall survival of approximately 83%. Drug expenditure decreased by approximately 90% versus standard dosing without excess severe toxicity.

The NIVIPIT trial, a randomized, multicenter phase 1b trial, explored a different approach to dose reduction in previously untreated metastatic melanoma. Patients were randomized 2:1 to receive intravenous nivolumab combined with either intratumoral low-dose ipilimumab (a tenfold lower dose) or standard intravenous ipilimumab. The trial met its primary safety endpoint: grade 3–4 treatment-related adverse events at 6 months occurred in 22.6% with intratumoral ipilimumab versus 57.1% with intravenous ipilimumab. Cumulative grade 3–4 toxicity was 32.5% versus 66.6%. Response rates in injected lesions reached 65.7%, and response in uninjected lesions was 50%, suggesting an abscopal-like systemic immune effect. At a median follow-up of 55.5 months, there was no significant difference in progression-free survival or overall survival between arms. Pharmacokinetic analysis confirmed markedly lower systemic ipilimumab exposure in the intratumoral arm.

The biological rationale for ultra-low-dose approaches is supported by early pharmacokinetic studies showing that PD-1 receptor occupancy reaches biologically active levels even at doses far below currently approved regimens. Doses as low as 0.1 mg/kg achieved approximately 64–70% PD-1 receptor occupancy, with minimal additional biological gain at higher exposures. The serum concentration required for clinical efficacy is estimated around 1.2 μg/mL, while standard approved dosing generates concentrations approaching 33.7 μg/mL — nearly 30-fold higher than theoretically necessary for immune activation.

In many low- and middle-income countries, including India, only 1–3% of eligible patients can access full-dose immunotherapy because of cost constraints. The Indian phase III trial of ultra-low-dose nivolumab demonstrated cost reductions approaching 90% versus standard dosing. However, no direct randomized comparison of low- versus standard-dose nivolumab exists, and cross-trial comparisons with CheckMate-141 or KEYNOTE-048 cannot establish non-inferiority or superiority. Generalizability beyond HNSCC and LMIC settings remains unclear.